Profile of Circulating Levels of Interleukin-1 Receptor Antagonist and Interleukin-6 in Colorectal Cancer Patients

References

• Oka M, Iizuka N, Yamamoto K, et al. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996;16:1001–6.
   PubMed Web of Science ®Google Scholar
• Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83–5.
   PubMed Web of Science ®Google Scholar
• Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989;250:607–10.
   PubMed Web of Science ®Google Scholar
• Reichner JS, Mulligan JA, Palla ME, Hixson DC, Albina JE, Bland KI. Interleukin-6 production by rat hepatocellular carcinoma cell is associated with metastatic potential but not with tumorigenicity. Arch Surg 1996;131:360–5.
   PubMedGoogle Scholar
• Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure free survival in indolent lymphoma. Leukemia Lymphoma 1998;30: 56–571.
   Google Scholar
• Hoheisel G, Izbicki G, Roth M, et al. Proinflammatory cytokine levels in patients with lung cancer and carcinomatous pleurisy. Respiration 1998;65:183–6.
   PubMed Web of Science ®Google Scholar
• Akimoto S, Okumura A, Fuse H. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocrine J 1998;45: 183–9.
   Google Scholar
• Lissoni P, Rovelli F, Tisi E, et al. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors. J Biol Regul Homeost Agents 1995;9:146–14.
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects tumor proliferative activity in colorectal cancer patients. Cancer 1999;85: 2526–31.
   Google Scholar
• Jordan M, Otterness IG, Ng R, et al. Neutralization of endogenous IL-6 suppresses induction of IL-1 receptor antagonist. J Immunol 1995;154:4081–90.
   PubMed Web of Science ®Google Scholar
• Rimaniol AC, Zylberberg H, Rabian C, et al. Imbalance between IL-1 and IL-1 receptor antagonist in the cerebrospinal fluid of HIV-infected patients. J Acq Immune Def Synd 1997;16:340–2.
   Web of Science ®Google Scholar
• Lu ZY, Bataille R, Poubelle P, et al. An interleukin 1 receptor antagonist blocks the IL-1 induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. Stem Cells 1995;2:28–34.
   Google Scholar
• Yin M, Gopal V, Banavali S, et al. Effects of an IL-1 receptor antagonist on acute myeloid leukemia cells. Leukemia 1992;6:898–901.
   PubMed Web of Science ®Google Scholar
• Vidal-Vanaclocha F, Amezaga C, Asumendi A, et al. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res 1994;54: 2667–72.
   Google Scholar
• Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 as an antiinflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113–8.
   PubMed Web of Science ®Google Scholar
• Nowacki MP, Janik P, Nowacki PM. Inflammation and metastases. Med Hypotheses 1996;47:193–6.
   PubMed Web of Science ®Google Scholar
• Vidal-Vanaclocha F, Alvarez A, Asumendi A, et al. Interleukin 1-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. J Natl Cancer Inst 1996;88: 198–205.
   Google Scholar
• von Biberstein SE, Spiro JD, Lindquist R, et al. Interleukin-1 receptor antagonist in head and neck squamous cell carcinoma. Arch Otolaryngol 1996;122:751–9.
   Google Scholar
• Iwagaki H, Hizuta A, Tanaka N. Interleukin-1 receptor antagonists and other markers in colorectal cancer patients. Scand J Gastroenterol 1997;32: 577–81.
   Google Scholar
• von Biberstein SE, Spiro JD, Lindquist R, Kreutzer DL. Interleukin-1 receptor antagonist in head and neck squamous cell carcinoma. Arch Otolaryngol 1996;122:751–9.
   Google Scholar
• Falconer JS, Fearon KC, Plester CE, et al. Cytokines, the acute phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994;219:325–31.
   PubMed Web of Science ®Google Scholar
• Staal-van den Brekel AJ, Dentener MA, et al. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995;13:2600–5.
   Google Scholar
• Wigmore SJ, Fearson KC, Maingay JP, et al. Down regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 1997;92:215–21.
   PubMed Web of Science ®Google Scholar
• Fujiki F, Mukaida N, Hirose K, et al. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res 1997;57:94–9.
   PubMed Web of Science ®Google Scholar
• Tamura K, Shibata Y, Matsuda Y, Ishida N. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluid of cancer patients. Cancer Res 1981;41:3244–52.
   PubMed Web of Science ®Google Scholar
• Oka M, Mitsunaga H, Hazama S, Yoshino S, Suzuki T. Natural killer activity and serum immunosuppressive acidic protein levels in esophageal and gastric cancers. Jpn J Surg 1993;23:669–74.
   Google Scholar
• Henderson B, Thompson RC, Hardingham T, et al. Inhibition of interleukin-1 induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine 1991;9:246–9.
   Web of Science ®Google Scholar
• Alexander HR, Doherty GM, Venzon DJ, et al. Recombinant interleukin-1 receptor antagonist: effective therapy against gram-negative sepsis in rats. Surgery 1992;112:188–94.
   PubMed Web of Science ®Google Scholar
• Cominelli F, Nast CC, Duchini A, et al. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992;103:65–71.
   PubMed Web of Science ®Google Scholar